Barclays PLC Exagen Inc. Transaction History
Barclays PLC
- $353 Billion
- Q1 2025
A detailed history of Barclays PLC transactions in Exagen Inc. stock. As of the latest transaction made, Barclays PLC holds 5,145 shares of XGN stock, worth $35,706. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,145
Previous 5,145
-0.0%
Holding current value
$35,706
Previous $21,000
14.29%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding XGN
# of Institutions
40Shares Held
6.17MCall Options Held
3.4KPut Options Held
18.4K-
Rtw Investments, LP New York, NY1.51MShares$10.5 Million0.09% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A6891KShares$6.19 Million0.01% of portfolio
-
Silvercrest Asset Management Group LLC New York, NY532KShares$3.69 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA491KShares$3.41 Million0.0% of portfolio
-
Morgan Stanley New York, NY486KShares$3.37 Million0.0% of portfolio
About EXAGEN INC.
- Ticker XGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 16,260,400
- Market Cap $113M
- Description
- Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...